Literature DB >> 2376049

Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin.

F Sutherland1, K Borkenhagen, L Temple, L D Bryant, R Lafreniere.   

Abstract

Lymphokine-activated killer cells appear to arise from precursor cells bearing natural killer (NK) cell antigens. Cyclosporin (CsA) is a well-known immunosuppressive agent that can down-regulate NK cell cytotoxicity. Studies were initiated to evaluate the effects of CsA on splenocytes before and after exposure to recombinant interleukin-2 (rIL-2). Normal C57BL/6 mice receiving CsA at a dose of 100 mg/kg demonstrated a decrease in NK cell lysis against the YAC-1 lymphoma target in a 4-h chromium-release assay. When splenocytes obtained from CsA-treated mice were cultured for 3 days in complete medium containing 1000 U rIL-2/ml, they demonstrated a return of NK cell lysis to normal (mean cytotoxicity = 65 LU versus 60 LU for control and CsA-exposed splenocytes respectively; P, NS, five consecutive experiments) but revealed a decrease in the lysis of a NK-resistant target: the MCA-102 sarcoma (mean cytotoxicity = 20 LU vs 12 LU for control and CsA-exposed splenocytes respectively; P less than 0.02, five consecutive experiments). Fresh splenocytes cultured in media containing rIL-2 and CsA demonstrated a decrease in proliferation, cell-cycle S-phase fraction and cell yields compared to splenocytes cultured in media containing rIL-2 alone. In addition, a decrease in tumor cell lysis for NK-cell sensitive (mean percentage lysis = 98% vs 60%, rIL-2 vs rIL-2 + CsA; effector-to-target ratio 100: 1) and resistant targets (mean percentage lysis = 68% vs 28%, rIL-2 vs rIL-2 + CsA; effector-to-target ratio 100: 1) was also seen. CsA had no effects on the phenotypic antigenic expression of splenocytes cultured with high-dose rIL-2 although activated T cell antigens were down-regulated when fresh splenocytes were evaluated after in vivo exposure to CsA. These studies support the down-regulating effects of CsA on NK cell lysis and suggest that the rIL-2-activated cell population is heterogeneous as demonstrated by the differential down-regulation and recovery of NK-resistant cell lysis versus NK-sensitive cell lysis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2376049     DOI: 10.1007/bf01740940

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

1.  A phenyl-beta-galactoside-specific monoclonal antibody reactive with murine and rat NK cells.

Authors:  V E Miller; A E Lagarde; B M Longenecker; A H Greenberg
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

Review 2.  Cancers after cyclosporine therapy.

Authors:  I Penn
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

3.  Cyclosporine-cyclophilin interaction.

Authors:  V F Quesniaux; M H Schreier; R M Wenger; P C Hiestand; M H Van Regenmortel
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

Review 4.  Human natural killer cells: biologic and pathologic aspects.

Authors:  G Trinchieri; B Perussia
Journal:  Lab Invest       Date:  1984-05       Impact factor: 5.662

5.  Natural cell-mediated cytotoxicity and suppressor activity for natural cell-mediated cytotoxicity in long-term renal transplant patients.

Authors:  Y Ono; R H Kerman; B D Kahan
Journal:  Transplantation       Date:  1982-08       Impact factor: 4.939

6.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

Authors:  R Lafreniere; S A Rosenberg
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

7.  Inhibition of mouse natural killer activity by cyclosporin A.

Authors:  R H Yanagihara; W H Adler
Journal:  Immunology       Date:  1982-02       Impact factor: 7.397

8.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

9.  Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.

Authors:  N L Vujanovic; R B Herberman; M W Olszowy; D V Cramer; R R Salup; C W Reynolds; J C Hiserodt
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

10.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.